Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2016-01-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Establishment of registration database online.
2. Participants will be enrolled according to the inclusion criteria and exclusion criteria.
3. The following data will be collected prospectively, including demographic data, clinical symptoms, physical examination, laboratory examination, renal pathology, treatment protocol and follow-up.
4. SPSS software (version 14.0; SPSS, Inc., Chicago, IL, USA) will be used for statistical analysis. P value less than 0.05 will be considered significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
corticosteroid
pediatric IgA nephropathy treated with only corticosteroid
Corticosteroid
Dipyridamole
ACE Inhibitor or Angiotensin receptor antagonist
corticosteroid and cyclophosphamide
pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
Corticosteroid
Cyclophosphamide
Dipyridamole
ACE Inhibitor or Angiotensin receptor antagonist
corticosteroid and mycophenolate mofetil
pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
Corticosteroid
Mycophenolate mofetil
Dipyridamole
ACE Inhibitor or Angiotensin receptor antagonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Corticosteroid
Cyclophosphamide
Mycophenolate mofetil
Dipyridamole
ACE Inhibitor or Angiotensin receptor antagonist
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting with nephrotic proteinuria, defined as 24-hour urinary protein\>50mg/kg, or UPC\>2.0 mg/mg.
* Informed consent must be signed.
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing PLA General Hospital
OTHER
Beijing Children's Hospital
OTHER
Central South University
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Tongji Hospital
OTHER
Hunan Children's Hospital
OTHER_GOV
Shanghai Children's Hospital
OTHER
Nanjing Children's Hospital
OTHER
Children's Hospital of Chongqing Medical University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Fuzhou General Hospital
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Children's Hospital of Hebei Province
OTHER
Guangzhou Women and Children's Medical Center
OTHER
Jiangxi Province Children's Hospital
OTHER
Guangzhou First People's Hospital
OTHER
Xian Children's Hospital
OTHER_GOV
Capital Institute of Pediatrics, China
OTHER
The First Hospital of Jilin University
OTHER
Wuhan Women and Children's Medical Center
OTHER
Tianjin Children's Hospital
OTHER
Chengdu Women's and Children's Central Hospital
OTHER
The First People's Hospital of Yunnan
OTHER
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jie Ding
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Ding, Prof.
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xuhui Zhong, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015[992]
Identifier Type: -
Identifier Source: org_study_id